Test of an implanted eye device plus vision training for AMD
Part of Eyes & vision clinical trials.
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 65 or older at the pre-surgery visit
- Have late-stage AMD in both eyes with central vision loss (scotomas) involving the middle of vision
- Have no signs that new abnormal blood vessel growth (CNV) is active in the past 6 months, based on eye checks and scans
- For the implanted eye: have a significant cataract and be willing to do telescope-based training with a vision specialist
- Have enough peripheral (side) vision to move around safely for the eye that is not implanted
- Be able to understand consent and follow post-surgery vision training
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
This post-market study looks at how well a telescope-like eye implant (NG SI IMT 3X) works for people with very advanced age-related macular degeneration that affects the center of vision, plus cataracts. The implant is placed in one eye, and you’ll get training to learn how to use it after surgery.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.